Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib versus chemotherapy in FGFR-positive advanced urothelial carcinoma after platinum therapy
NL-OMON46559Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rogaratinib in transitional cell carcinoma (TCC) and bladder cancer (2 arms), sponsored by Bayer. Primary endpoint: Overall survival. Started Jan 2019; status: completed.
02
Drugs
rogaratinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON46559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46559.